Strs Ohio Alector, Inc. Transaction History

Strs Ohio

$24.7 Billion
Q1 2024

A detailed history of Strs Ohio transactions in Alector, Inc. stock. As of the latest transaction made, Strs Ohio holds 91,200 shares of ALEC stock, worth $395,808. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,200

Previous 73,200 24.59%

Holding current value

$395,808

Previous $584,000 5.99%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$5.69 - $8.08 $102,420 - $145,440	18,000 Added 24.59%	91,200 $549,000
Q2 2023 Jul 31, 2023	BUY	$5.86 - $7.93 $428,952 - $580,476	73,200 New	73,200 $439,000
Q1 2023 Aug 02, 2023	SELL	$5.85 - $9.84 $33,345 - $56,088	-5,700 Reduced 7.79%	67,500 $417,000
Q4 2022 Jan 26, 2023	SELL	$6.88 - $9.55 $37,152 - $51,570	-5,400 Reduced 7.41%	67,500 $623,000
Q3 2022 Oct 27, 2022	BUY	$8.19 - $13.2 $33,579 - $54,120	4,100 Added 5.96%	72,900 $689,000

Q2 2022 Jul 25, 2022	BUY	$7.65 - $14.24 $58,140 - $108,224	7,600 Added 12.42%	68,800 $699,000
Q1 2022 Apr 21, 2022	BUY	$13.02 - $20.78 $246,078 - $392,742	18,900 Added 44.68%	61,200 $872,000
Q4 2021 Jan 24, 2022	BUY	$19.35 - $25.54 $663,705 - $876,022	34,300 Added 428.75%	42,300 $873,000
Q3 2021 Oct 22, 2021	BUY	$21.65 - $39.49 $173,200 - $315,920	8,000 New	8,000 $182,000
Q3 2020 Dec 14, 2020	SELL	$10.54 - $24.96 $89,590 - $212,160	-8,500 Closed	0 $0
Q2 2020 Jul 23, 2020	BUY	$21.87 - $33.11 $185,895 - $281,435	8,500 New	8,500 $207,000
Q3 2019 Oct 21, 2019	SELL	$14.42 - $22.2 $21,630 - $33,300	-1,500 Closed	0 $0
Q1 2019 Apr 19, 2019	BUY	$15.97 - $22.5 $23,955 - $33,750	1,500 New	1,500 $28,000

Others Institutions Holding ALEC

# of Institutions

161

Shares Held

59.8M

Call Options Held

67.8K

Put Options Held

200

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $358M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account